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ADevelopment of Replication-Defective Adenovirus Serotype 5 Containing the Capsid and 3C
Protease Coding Regions of Foot-and-Mouth Disease Virus as a Vaccine Candidate
Gregory A. Mayr, Jarasvech Chinsangaram, and Marvin J. Grubman1
Plum Island Animal Disease Center, USDA, ARS, NAA, PO Box 848, Greenport, New York 11944
Received June 7, 1999; returned to author for revision June 29, 1999; accepted July 27, 1999
A recombinant replication-defective human adenovirus serotype 5 vector containing FMDV capsid, P1-2A, and viral 3C
protease coding regions was constructed. Two viral clones were isolated, Ad5-P12X3CWT, containing the wild-type (WT) 3C
protease that processes capsid polyprotein precursor into mature capsid proteins, and Ad5-P12X3CMUT, containing a point
mutation in the protease coding region that inhibits processing. In 293 cells infected with either virus, synthesis of the FMDV
capsid polyprotein precursor occurred, but processing of the polyprotein into structural proteins VP0, VP3, and VP1 occurred
only in 3CWT virus-infected cells. Immunoprecipitation with monospecific and monoclonal antibodies indicates possible
higher order structure formation in Ad5-P12X3CWT virus-infected cells. The viruses were used to elicit immune responses
in mice inoculated intramuscularly (im). Only virus containing the 3CWT elicited a neutralizing antibody response. After
boosting, this neutralizing antibody response increased. Swine inoculated im with Ad5-P12X3CWT virus developed a
neutralizing antibody response and were either completely or partially protected from contact challenge with an animal
directly inoculated with virulent FMDV. This adenovirus vector may be an efficient system for the delivery of FMDV cDNA into
animals, leading to a high level of neutralizing antibody production and protection from FMDV challenge. © 1999 Academic Press
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Foot-and-mouth disease virus (FMDV) is a positive-
trand RNA virus which causes a highly contagious dis-
ase affecting cloven-hoofed animals, of which cattle,
igs, and sheep are particularly important for economic
easons. In countries where the disease has not been
radicated, vaccination plays a crucial role in its control.
ven in countries where no FMD is currently present, it
s necessary to maintain a strategy for vaccination in
ase of an outbreak (Barteling and Vreeswijk, 1991), as
ccurred in 1997 in Taiwan (Dunn and Donaldson, 1997).
urrent vaccines, which are very effective, are chemi-
ally inactivated FMDV (Barteling and Vreeswijk, 1991).
here are, however, problems with this approach, includ-
ng inadvisability of producing such vaccines in countries
here the disease has been eradicated due to the pos-
ibility of incomplete inactivation or virus escape from
accine-producing facilities (Beck and Strohmaier, 1987;
ing et al., 1981). Until recently (Lubroth and Brown,
995), it has also been difficult to distinguish between
nfected and vaccinated animals, necessitating the de-
truction of both after a successful ring vaccination pro-
edure (Barteling and Vreeswijk, 1991). In addition, since
MDV is an RNA virus, repeated passage in tissue cul-
ure can lead to antigenic variation (Bolwell et al., 1989).
1 To whom reprint requests should be addressed at PIADC, USDA,
RS, NAA, PO Box 848, Greenport, NY 11944-0848. Fax: (516) 323-2507.
-mail: mgrubman@asrr.arsusda.gov.
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496he use of cDNA or protein subunit vaccines eliminates
number of the above problems. For these reasons,
everal approaches are being examined which attempt
o use subunits of the virus, either as protein (Bachrach
t al., 1975; Brown, 1992; Doel and Chong, 1982; Francis
t al., 1987; Grubman et al., 1993; Kleid et al., 1981; Lewis
t al., 1991; Mulcahy et al., 1990; Roosien et al., 1990;
weyemamu et al., 1979) or as DNAs (Abrams et al.,
995; Chinsangaram et al., 1998), which could be manu-
actured in an FMDV-free setting without risk to sur-
ounding areas and which could elicit a strong and
ong-lived neutralizing antibody response in animals.
Studies with traditional FMD vaccines have shown
hat protection in vaccinated animals correlates with the
evelopment of a strong neutralizing antibody response
Ahl et al., 1983; Pay et al., 1983; Sutmoller et al., 1983;
utmoller and Vieira, 1980). These antibodies are impor-
ant for direct inactivation of the virus and antibody–virus
omplex activation of the macrophage phagocytic path-
ay (reviewed, McCullough et al., 1992). It has previously
een shown that FMDV empty capsids, virus particles
acking nucleic acid, are capable of eliciting the same
ntibody response as infectious FMDV particles (Doel
nd Chong, 1982; Rowlands et al., 1975; Rweyemamu et
l., 1979). Based on these results, our approach toward
he development of subunit vaccines has been to include
he capsid coding region, P1-2A, and the 3C protease
oding region, necessary for processing P1 to the capsid
roteins VP0, VP3, and VP1, in a cDNA construct (Fig. 1).A limitation of using naked FMDV DNA encoding
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497Ad5-FMDV AS A VACCINE CANDIDATE1-2A and 3C to directly vaccinate animals has been the
eed to use large amounts of DNA when inoculating by
raditional intramuscular (im), subcutaneous, and intra-
eritoneal routes to facilitate production of FMDV anti-
ens. It has been shown that the use of gene gun
echnology can facilitate the use of lower levels of DNA
Chinsangaram et al., 1998), but the antibody response is
ess optimal than with traditional vaccines.
The use of adenovirus vectors for DNA vaccine deliv-
ry is being rapidly explored in a variety of fields
Alkhatib and Briedis, 1988; Cheng et al., 1992; Chengal-
ala et al., 1994; Gonin et al., 1995; Jacobs et al., 1992;
ubeck et al., 1989; Papp et al., 1997; Prevec et al., 1989,
990; Sheppard et al., 1998). The advantage of this ap-
roach as opposed to naked DNA vaccines is that hu-
an adenovirus vectors are able to bind to and internal-
ze in cells of several animal species, thus ensuring rapid
ptake and expression of the desired genes. In addition,
ntigenic variation among human adenoviruses and an-
mal adenoviruses is sufficient such that animals should
ot be primed against human adenovirus infection.
hese facts, combined with the use of replication-defec-
ive, E1-deleted adenoviruses, which can replicate only
n E1-complementing human cells (e.g., 293) in tissue
ulture, suggest that the vector cannot be spread from
ne animal to another, ensuring a measure of safety not
ecessarily seen in more traditional attenuated virus
accines.
In this paper we examine the ability of human adeno-
irus serotype 5 nonreplicating vectors containing the
MDV capsid and 3C protease DNA to elicit an FMDV-
pecific immune response in mice and swine. We have
FIG. 1. Schematic representation of FMDV genome and polyprotein
rocessing. Line 1 is a graphic presentation of the FMDV genome and
he regions corresponding to component protein segments of the
olyprotein. Line 2 represents the P12X3C construct, containing an
rtificial start codon (AUG) upstream of the P1 coding region and an
rtificial stop codon (UAG) downstream of the 3C coding region. Part of
B (2B9) is fused with part of 3B (3B9) by the use of XhoI sites in those
wo regions. Line 3 represents the processing of the polyprotein by
rotease 2A self-cleavage. Only this processing can occur in con-
tructs containing the mutated 3C coding region (3CMUT). Line 4
epresents the further processing of the polyprotein effected by 3CWT
rotease.onstructed two adenovirus clones, one containing a aild-type 3C (WT) coding region (Ad5-P12X3CWT) and
he other containing a point mutation in the 3C coding
egion which results in an inactive protease (Ad5-
12X3CMUT). This study shows that both viruses can
roduce FMDV capsid proteins in infected cells and
nduce general antibody responses in mice after one
noculation, but processed capsid proteins and a neu-
ralizing antibody response are elicited only in mice in-
culated with Ad5-P12X3CWT. In swine, Ad5-P12X3CWT
s able to induce general and neutralizing antibody re-
ponses, as well as protection from FMDV challenge,
hus showing promise as an alternative FMD vaccine
andidate.
RESULTS
MDV protein expression in Ad5-P12X3C-infected
93 cells
Human 293 cells were infected at a multiplicity of
nfection (m.o.i.) of 25 with Ad5-P12X3CWT or Ad5-
12X3CMUT. After radiolabeling of infected cells with
35S]methionine, the cell lysate was immunoprecipitated
ith anti-VP2 (a-VP2) serum, which recognizes epitopes
n VP0. Anti-FMDV bovine convalescent serum and nor-
al rabbit serum were used as controls (Fig. 2, lanes 1
nd 2).
In Ad5-P12X3CWT-infected cells, P1-2A, VP0, VP3, and
P1 are synthesized (Fig. 2, lane 3). This result demon-
trates not only the production of P1-2A and processing
y the 3CWT protease to yield VP0, VP3, and VP1, but the
ikely formation of higher order structures as shown by
oprecipitation of VP0, VP3, and VP1 with a-VP2 serum.
FIG. 2. [35S]Methionine-labeled lysates of lane 1—FMDV A12-in-
ected LK cells immunoprecipitated with anti-FMDV bovine convales-
ent serum, lane 2—Ad5-P12X3CWT-infected 293 cells precipitated
ith normal rabbit serum, lane 3—Ad5-P12X3CWT-infected 293 cells
recipitated with anti-FMDV monospecific polyclonal a-VP2 serum,
ane 4—Ad5-P12X3CMUT-infected 293 cells precipitated with anti-
MDV monospecific polyclonal a-VP2 serum. The samples were ex-
mined by PAGE on a 15% gel. Positions of FMDV proteins are shown.
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498 MAYR, CHINSANGARAM, AND GRUBMANn Ad5-P12X3CMUT-infected cells, P1-2A is synthesized,
ut is not processed into VP0, VP3, and VP1 (Fig. 2, lane
). Processing occurs only in the presence of 3CWT
rotease.
Similar results were observed in infected HeLa cells, a
ell line nonpermissive for replication-defective adeno-
iruses (data not shown).
xamination of higher order capsid-like assembly
n Ad5-FMDV-infected 293 cells
As a method of assaying for FMDV capsid formation,
e used monospecific polyclonal or monoclonal antibod-
es (mAb) against FMDV structural proteins. In Fig. 3 it
an be seen that a-VP1 and a-VP2 monospecific anti-
odies both precipitate VP0, VP3, and VP1 from [35S]me-
hionine-labeled Ad5-P12X3CWT-infected 293 cell ex-
racts (Fig. 3, lanes 1 and 2). This result suggests that
ach of the monospecific polyclonal antibodies recog-
izes a capsid structure or aggregate containing all three
roteins. MAb 6EE2, which recognizes an epitope on
P1 (Baxt et al., 1989), also precipitates all three proteins
Fig. 3, lane 3). Last, mAb 2PD11, which is a conforma-
ion-dependent antibody that recognizes an epitope
ound on the surface of intact virus particles that includes
egions of VP3 and VP1 (Baxt et al., 1989), precipitates
P0 as well as VP3 and VP1 (Fig. 3, lane 4). This further
ndicates that at least some of the capsid proteins are
resent in a particle form which is structurally and anti-
enically similar to intact capsids.
In contrast, a-VP1 and a-VP2 antibodies immunopre-
35
FIG. 3. [35S]Methionine-labeled lysates from 293 cells infected with
d5-P12X3CWT virus (lanes 1–4) or Ad5-P12X3CMUT virus (lanes 5–8),
mmunoprecipitated with various antibodies. Lanes 1 and 5—lysate
recipitated with monospecific polyclonal a-VP1, lanes 2 and 6—lysate
recipitated with monospecific polyclonal a-VP2, lanes 3 and 7—lysate
recipitated with mAb 6EE2, lanes 4 and 8—lysate precipitated with
Ab 2PD11. Lane 9 is FMDV A12-infected LK cell lysate precipitated
ith anti-FMDV bovine convalescent serum as a marker. These sam-
les were examined by PAGE on a 15% gel. Positions of FMDV proteins
re shown.ipitate only P1-2A from [ S]methionine-labeled Ad5- b12X3CMUT-infected 293 cell extracts, further demon-
trating the absence of processing with this virus (Fig. 3,
anes 5 and 6). Interestingly, the mAb 6EE2 immunopre-
ipitates very little P1-2A, possibly the result of the spec-
ficity of this antibody for protein in the native conforma-
ion (Fig. 3, lane 7) (Baxt et al., 1989). Most significant is
he nearly complete absence of signal after immunopre-
ipitation with mAb 2PD11 (Fig. 3, lane 8), providing
dditional support for the specificity of this antibody for a
tructural motif present only on virus capsids.
Previously we showed, by sucrose gradient analysis,
hat it was possible to form low levels of empty capsid
tructures in bacteria transformed with an expression
ector containing an almost identical FMDV P12X3CWT
DNA construct (Lewis et al., 1991). In similar experi-
ents, 293 cells infected with Ad5-P12X3CWT vector
ielded very low levels of structures which migrated at
he same position as FMDV empty capsids. However, the
agnitude of the peak varied between experiments and
t was not always possible to detect these structures.
ntramuscular inoculation of BALB/c mice with
d5-P12X3CWT or Ad5-P12X3CMUT virus:
vidence of an immune response
To determine if Ad5-P12X3CWT and/or Ad5-
12X3CMUT virus can induce an FMDV-specific immune
esponse, 9-week-old BALB/c mice (certified murine
denovirus-free) were inoculated im (five/group) with 5 3
07 pfu/mouse of either virus in 50 ml of 13 phosphate-
uffered saline (PBS). As a control, two mice were in-
ected im with PBS. The mice were bled at 3 and 5 weeks
ostinoculation, boosted at 6 weeks with an equivalent
mount of virus, and bled at weeks 8, 11, and 21. Individ-
al sera from the mice were screened by radioimmuno-
recipitation (RIP) at 3 and 5 weeks postinoculation and
ooled serums from each group were assayed by plaque
eduction neutralization (PRN) assay. Five-week serum
rom individual mice, except the representative control
ouse, contained antibodies against the FMDV struc-
ural proteins VP0, VP3, and VP1 (Fig. 4), indicating that
he mice inoculated with Ad5-P12X3CWT (Fig. 4, lanes
–7) and Ad5-P12X3CMUT (Fig. 4, lanes 8–12) developed
n immune response to the expressed FMDV proteins.
he 3-week sera showed the same results, although
ignals with these sera were weaker (data not shown).
he control mouse group never developed antibody to
MDV proteins.
By PRN, only the Ad5-P12X3CWT virus-inoculated
ice developed a low but detectable neutralizing anti-
ody response by 5 weeks postinoculation (Fig. 5). Two
eeks following the boost, at week 8, there was a dra-
atic increase in the level of neutralizing antibody in the
d5-P12X3CWT-inoculated group (Fig. 5). Sera of individ-
al Ad5-P12X3CWT-inoculated mice from week 5 (pre-
oost) and week 8 (postboost) were compared. Although
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499Ad5-FMDV AS A VACCINE CANDIDATEhere was variation in titers between individual mice,
here is a clear increase in titers after the boost, from a
ean titer of 40 in week 5 to a mean titer of 896 in week
(data not shown). Furthermore, the titer of the Ad5-
12X3CWT-inoculated group increased by week 11 (Fig.
). In contrast, the control mice and Ad5-P12X3CMUT-
noculated mice never developed any neutralizing anti-
ody response (Fig. 5).
It is worth noting that at 21 weeks (15 weeks post-
oost) the Ad5-P12X3CWT-inoculated group still had a
FIG. 4. Individual mouse sera from 5 weeks postinoculation were
sed to immunoprecipitate [35S]methionine-labeled lysates from FMDV
12-infected LK cells. Lane 1—marker lane of lysate precipitated with
nti-FMDV bovine convalescent serum. Lanes 2–12 are lysate precip-
tated with the following mouse sera: lane 2—individual control mouse
era representative of the control group; lanes 3 to 7—sera from
ndividual mice inoculated with Ad5-P12X3CWT; lanes 8 to 12—sera
rom individual mice inoculated with Ad5-P12X3CMUT. The samples
ere examined by PAGE on a 15% gel.
FIG. 5. Pooled mouse sera groups from 3, 5, 8, 11, and 21 weeks pos
ntibody present. Values are shown as the highest fold dilution of seradentification of virus used.ignificant neutralizing antibody titer against FMDV (PRN
f 1:320) (Fig. 5). This suggests that the adenovirus
accine may impart long-lasting immunity against FMDV
o inoculated animals.
xamination of the potency and efficacy
f Ad5-P12X3CWT in swine
To demonstrate the potential of Ad5-P12X3CWT as a
accine candidate, two groups of swine, three animals
er group, were inoculated im with either 1 3 108 pfu/
wine Ad5-P12X3CWT or PBS. The animals were all
oused in the same room to experimentally demonstrate
he inability of the replication-defective virus to spread
rom the inoculated group to the uninoculated control
roup and, upon challenge, to expose the vaccinated
nd uninoculated control animals to high and sustained
evels of virulent animal-passaged FMDV. Swine inocu-
ated with Ad5-P12X3CWT developed a significant
MDV-specific neutralizing antibody response by 2
eeks postinoculation (Fig. 6A). The titers decreased
ith time, increased 2- to 8-fold after the boost, and
tabilized prior to challenge. The control group did not
evelop neutralizing antibody against FMDV (Fig. 6B).
he Ad5-P12X3CWT-inoculated animals developed an
ntibody response against the FMDV structural proteins
y 2 weeks postinoculation as assayed by RIP (data not
hown), while the control group did not develop an
MDV-specific immune response as measured by RIP
ven by 8 weeks postinoculation (Fig. 7, lanes 5–7).
ikewise, the three control swine did not develop any
ation were used in a PRN assay to determine the level of neutralizing
resulted in a 70% reduction in plaque formation. Refer to the key fortinocul
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500 MAYR, CHINSANGARAM, AND GRUBMANeutralizing antibodies against adenovirus, further proof
hat the vaccine does not spread from the inoculated
nimals (data not shown).
Control animal 3 was infected with virulent cattle-
assaged A12 virus. It developed a fever of 40°C by 2
ays postchallenge (dpc), lesions on all four feet by 3
pc, and on the snout by 5 dpc. The remaining two
ninoculated control animals developed a fever of over
0°C and vesicular lesions on all four feet by 4 dpc.
In contrast, the vaccinated animals were significantly
rotected from clinical disease. One of the vaccinated
nimals, WT 3, did not develop any clinical signs of FMD,
hile the other two animals in this group developed FMD
ut, as reflected in the clinical observations, the disease
igns were significantly reduced compared to the ani-
als in the control group, i.e., no fever and limited num-
er of digits with lesions (Table 1).
Serological analysis demonstrated that after challenge
FIG. 6. (A) Individual Ad5-P12X3CWT-inoculated swine sera from 0–8
o determine the level of neutralizing antibody present. Values are sho
laque formation. Refer to the key for identification of swine. (B) In
ostchallenge were used in a PRN assay to determine the level of neutr
hich resulted in a 70% reduction in plaque formation. Refer to the kehe directly inoculated swine as well as the two uninocu- 1ated control animals seroconverted, i.e., all had a sig-
ificant FMDV-specific neutralizing antibody response
Table 1) and antibodies against the structural and, for
ontrols 2 and 3, nonstructural proteins (Fig. 7, lanes
1–13 and 17–19). The PRN titer of the vaccinated animal
hat was completely protected from disease increased
nly fivefold after challenge (Table 1). The PRN titers of
he vaccinated animals that developed clinical FMD in-
reased, indicating a level of FMD replication. The in-
rease in the PRN titer may, in part, also reflect contin-
ous exposure to the control swine which were actively
nfected and shedding virus.
DISCUSSION
It is important on an international scale to maintain a
eady state of protection against FMD. As was recently
een with the outbreak in Taiwan (Dunn and Donaldson,
postinoculation and 1 week postchallenge were used in a PRN assay
the highest fold dilution of sera which resulted in a 70% reduction in
l control swine sera from 0–8 weeks postinoculation and 1 week
antibody present. Values are shown as the highest fold dilution of sera
entification of swine.weeks
wn as
dividua
alizing997), even countries which have been FMDV free for
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501Ad5-FMDV AS A VACCINE CANDIDATEears are susceptible to the devastation which occurs
uring a chance outbreak of the disease. Generally, for
afety reasons, countries which are FMDV free do not
roduce vaccine. In large part this is due to concern over
mproperly inactivated virus or escape of virus from the
roduction facilities (King et al., 1981). DNA vaccines and
ecombinant adenovirus vectors containing only a por-
ion of the FMDV genome, i.e., empty viral capsid coding
egions, may offer an alternative to these problems, by
llowing the production of antigenic empty capsid struc-
FIG. 7. Individual swine sera from 8 weeks postinoculation (wpi)
35S]methionine-labeled lysates from FMDV A12-infected LK cells. Lane
erum; lanes 2 to 4—lysate precipitated with 8-wpi individual sera fro
recipitated with 8-wpi individual sera from control swine 1–3, respe
d5-P12X3CWT-inoculated swine 1–3, respectively; lanes 11 to 13—
espectively; lanes 14 to 16—lysate precipitated with 2-wpc individua
9—lysate precipitated with 2-wpc individual sera from control swine
T
Summary of Immune and Clinical R
Swine Vaccine
Prechallenge
PRNa
0 wpie
PRNa
8 wpie
RIPb 8 wpie
(s/ns)
T1 P12X3CWT ,4 128 1/2
T2 P12X3CWT ,4 256 1/2
T3 P12X3CWT ,4 256 1/2
1 None 8 8 2/2
2 None 4 ,4 2/2
3 None ,4 4 2/2
a The number listed is the highest fold dilution resulting in a plaque
b A positive result indicates that the sera from this animal is able
roteins VP0, VP1, VP3. ns, nonstructural proteins 3D and/or 2C.
c Fever is scored as 2 or more consecutive days of temperature ove
d The lesion score is the number of digits on which the swine exhib
e wpi, weeks postinoculation.
f wpc, weeks postchallenge.ures without the possibility of FMD viral infectivity. A
otential benefit of using replication-defective human
denovirus serotype 5 vectors is that the virus itself is
ncapable of replication except in 293 cells, yet it retains
he ability to attach to and internalize into cells of a
umber of species (Haj-Ahmad and Graham, 1986; Pre-
ec et al., 1989, 1990).
In this study, we have examined the possibility of using
human adenovirus serotype 5 replication-defective
ector containing the coding regions of the FMDV capsid
and 2 weeks postchallenge (wpc) were used to immunoprecipitate
arker lane of lysate precipitated with anti-FMDV bovine convalescent
-P12X3CWT-inoculated swine 1–3, respectively; lanes 5 to 7—lysate
; lanes 8 to 10—lysate precipitated with 1-wpc individual sera from
precipitated with 1-wpc individual sera from control swine 1–3,
from Ad5-P12X3CWT-inoculated swine 1–3, respectively; lanes 17 to
spectively. The samples were examined by PAGE on a 15% gel.
ses to Vaccination and Challenge
Postchallenge
Na
pc f
PRNa
2 wpc f
RIPb 2 wpc f
(s/ns) Feverc Lesion scored
28 10,240 1/2 2 2
28 10,240 1/2 2 1
28 1,280 1/2 2 0
56 25,600 1/2 1 16
28 25,600 1/1 1 16
92 12,800 1/1 1 16 1 snout
ion of 70%.
unoprecipitate protein as determined by PAGE analysis. s, structural
.
ions. Swine have 4 digits per foot.and 1
1—m
m Ad5
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l seraABLE 1
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502 MAYR, CHINSANGARAM, AND GRUBMANolyprotein and 3C protease. The Ad5-P12X3CWT virus
onstruct can infect 293 cells and produce and process
he FMDV polyprotein into capsid proteins VP0, VP3, and
P1. The Ad5-P12X3CMUT virus construct, which con-
ains a 3C coding region with a single inactivating point
utation, was able to infect 293 cells and produce the
MDV polyprotein, but processing was limited to the
leavage performed by 2A at its carboxyl terminus. Data
rom radioimmunoprecipitations of infected cell lysates
ndicate that in cells infected with the Ad5-P12X3CWT
irus, some higher order structures were formed, includ-
ng, at low levels, structures which share immunological
imilarity with empty capsids.
When the Ad-FMDV virus constructs were used to
mmunize mice, both viruses induced an immune re-
ponse as measured by radioimmunoprecipitation. How-
ver, by week 5 only the mice immunized with Ad5-
12X3CWT developed a neutralizing antibody response.
fter boosting at 6 weeks the Ad5-P12X3CWT-inoculated
roup showed a significant increase in neutralizing an-
ibody but the Ad5-P12X3CMUT-immunized group never
eveloped any neutralizing antibody response. It is of
nterest that the Ad5-P12X3CMUT virus-inoculated mice
o not develop a neutralizing antibody response, arguing
or the necessity of processing of the polyprotein in order
o generate this type of immunogenic response. We have
bserved this same result in mice inoculated with naked
NA containing the FMDV P12X empty capsid construct
nd WT or MUT 3C (Chinsangaram et al., 1998). Similarly
anz-Parra et al. recently constructed a replication-com-
etent Ad5 vector containing only the P1 region of FMDV
erotype C1 Oberbayern (Sanz-Parra et al., 1999). Inoc-
lation of cattle with this virus did not induce an antibody
esponse and only slightly reduced the severity of dis-
ase after challenge compared to uninoculated controls.
Interestingly, the immune response in the mice inoc-
lated with the Ad5-P12X3CWT virus shows longevity,
etaining a PRN of 1:320, even 15 weeks after the boost.
his result indicates that the adenovirus vectors may
acilitate a long-lived response in animals, making it all
he more ideal as a vaccine candidate.
The most significant result in this study was the effec-
iveness of the Ad5-P12X3CWT virus vector as a vaccine
andidate in swine. Ad5-P12X3CWT virus-inoculated
wine developed antibodies against FMDV structural
roteins and an FMDV-specific neutralizing antibody re-
ponse which seems to slightly increase by boosting the
wine with an equivalent dose of the Ad5-P12X3CWT
irus at 4 weeks post-initial inoculation. This vaccination
rotocol offered a significant degree of protection to the
igs against contact infection by the parental A12 virus
train. These pigs developed no fever, few if any lesions,
nd no antibodies against FMDV nonstructural proteins,
rguing for limited if any replication of FMDV in the
accinated animals. The control pigs by comparison de-
eloped fever, lesions on all digits, and seroconverted as reasured by PRN and RIP, and two of the pigs devel-
ped antibody against FMDV nonstructural proteins.
The difference in the boosting effect of the Ad5-
12X3CWT virus in mice as opposed to swine may result
rom preexposure of the swine to porcine adenovirus,
hereas the mice we utilized were certified murine ad-
novirus free. Preliminary studies indicate that prior to
noculation, the pigs have antibodies which cross-react
ith the Ad5 hexon as seen by RIP, but no neutralizing
ntibody to Ad5-P12X3CWT virus (data not shown). This
reexisting antibody against a different type of adenovi-
us may be sufficient to prime the pigs for a more rigor-
us response against adenovirus during the boosting
tage.
As we and others have demonstrated, the use of a
uman adenovirus serotype 5 vector allows gene deliv-
ry in laboratory animals including mice and cotton rats,
s well as in animals of economic importance, i.e., swine
nd cattle, even if the latter species have been previ-
usly exposed to ubiquitous animal adenoviruses (Mittal
t al., 1996; Prevec et al., 1989, 1990). Although the virus
sed in this study is replication defective except in 293
ells, it still retains the adenovirus particle’s ability to
ind to and be internalized by infected cells from various
pecies, including those, i.e., swine and bovine, suscep-
ible to FMDV (Gonin et al., 1995; Haj-Ahmad and Gra-
am, 1986; Jacobs et al., 1992; Prevec et al., 1989). Since
he FMDV sequences are cloned into the essential E1
egion, homologous recombination with a WT adenovi-
us, which is unlikely, could result only in a replication-
ompetent adenovirus with the deletion of the FMDV
equences. A more likely result would be animal adeno-
irus E1A facilitating limited transactivation of human
denovirus late genes (Zheng et al., 1994). However, the
wine potency and efficacy study used here was de-
igned to address the possibility of spread of the recom-
inant virus to uninoculated animals. Our results, Fig. 7,
emonstrate no seroconversion of the control swine to
MDV, even after two inoculations of vaccine trial swine.
ikewise, we saw no generation of a neutralizing anti-
ody response against human Ad5 in the control swine
data not shown), further indicating the absence of
pread of the Ad5-P12X3CWT vector from inoculated
nimals to naive animals. Since humans are widely ex-
osed to virulent serotypes of adenovirus at a young age,
he presence in the environment of a replication-defec-
ive human viral vector should pose no threat to humans
n its own (reviewed, Graham and Prevec, 1992). Our
esults indicate that the Ad5-FMDV construct is a viable
MD vaccine candidate, and in our ongoing studies we
re examining means of improving the potency and effi-
acy of this construct and developing improved Ad5-
MDV vectors, as well as vectors containing capsidegions from field isolates of FMDV.
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ells and viruses
All adenovirus clones were generated, grown, and
ested in human 293 cells (Graham and Prevec, 1991;
raham et al., 1977), of between passages 28 and 34.
xpression of FMDV proteins produced by adenovirus—
MDV hybrid viruses was also examined in human HeLa
ells. Plaque reduction neutralization of FMDV was per-
ormed on baby hamster kidney 21 cells of between
assages 67 and 82. [35S]Methionine-labeled FMDV-in-
ected cell lysate was made in secondary lamb kidney
LK) cells. The first three cell lines are available from the
merican Type Culture Collection. LK cells were ob-
ained from the Foreign Animal Disease Diagnostic Lab-
ratory at Plum Island.
Plasmids pCA3 and pJM17 (McGrory et al., 1988),
hich were used to generate the recombinant adenovi-
us clones, were purchased from Microbix Biosystems
nc. (Toronto, Canada).
deno–FMD hybrid virus production
The P12X3C cassette (Lewis et al., 1991), which con-
ains FMDV serotype A12 sequences, including the com-
lete P1, 2A, and 3C coding regions and partial 2B and
B coding regions, was engineered to contain an AUG
odon directly upstream of the P1 coding region and a
AG termination codon directly downstream of the 3C
oding region (Fig. 1). The P12X3C cassette is flanked by
n EcoRI restriction site upstream of the AUG and a
amHI restriction site downstream of the UAG. The
CWT protease coding region was replaced by a 3C
oding region containing a point mutation (C163G) in the
ctive site of the 3C protease (3CMUT) (Grubman et al.,
995). The polyprotein containing the C163G substitution
n 3C is unable to process the capsid coding region, and
nly the cleavage at the carboxyl terminus of 2A occurs
Ryan and Drew, 1994; Ryan et al., 1991). The engineered
12X3CWT and P12X3CMUT constructs were cloned into
he multiple cloning region of the plasmid pCA3, using
coRI and BamHI, thus placing the P12X3C genes under
ontrol of a human cytomegalovirus promoter. The plas-
ids were examined by restriction analysis, and the
resence of the C to G mutation at position 163 in the
CMUT construct was confirmed by sequencing. Co-
ransfection of pCA3-P12X3C and the plasmid pJM17
McGrory et al., 1988), which contains the entire Ad5
enome as well as the plasmid pBR322 DNA inserted
nto the E1 region, into 293 cells resulted in a homolo-
ous recombination event which yielded a replication-
efective Ad5-P12X3C virus containing the FMDV coding
egion in place of the early region 1 E1a and E1b genes
f adenovirus. The presence of the FMDV coding regions
n the virus DNA was determined by restriction analysis
nd PCR amplification using FMDV primers. Restriction vnalysis also demonstrated that there was no apparent
T Ad5 present in the virus population. The virus was
rown in 293 cells (Graham et al., 1977), to a titer of
reater than 109 pfu/ml. Virus was purified twice using a
onlinear CsCl gradient centrifugation procedure (Gra-
am and Prevec, 1991; Wilcox and Ginsberg, 1963). This
rocedure should be sufficient to remove the vast ma-
ority of adenovirus antigens as well as any FMDV anti-
ens produced. As proof of the absence of FMDV anti-
ens, dot blots were performed using 1.5 3 108 pfu of the
d5-P12X3CWT stock and 6 3 107 pfu of the A12 FMDV
tock. The blots were probed using FMDV-specific
onoclonal antibody 6EE2 and visualized with peroxi-
ase-conjugated anti-mouse antibody and ECL detection
ystem (Amersham International plc). There was no vis-
ble evidence of the presence of FMDV antigens in the
d5-P12X3CWT stock, while there was a strong signal
rom the A12-IC FMDV stock (data not shown).
Virus stocks were titered, in duplicate, by 10-fold serial
ilution on 293 cells. Furthermore, virus was titered on
eLa cells to look for WT Ad5 contamination, and it was
etermined to be approximately 1% compared to titers of
T adenovirus on 293 and HeLa cells.
adioimmunoprecipitation of [35S]methionine-labeled
d5-FMDV-infected cell lysates
To determine if FMDV proteins were synthesized and
rocessed, 293 cells at a density of 2 3 106 cells per
0-mm dish were infected with Ad5-P12X3CWT or Ad5-
12X3CMUT at a final m.o.i. of 25 pfu/cell for 5–6 h at
7°C. The cells were washed with methionine-free me-
ium and radiolabeled in methionine-free medium con-
aining 50–100 mCi/ml [35S]methionine for 60 min. The
ells were harvested and lysed, and equal amounts of
ounts per minute were immunoprecipitated using
MDV monospecific or monoclonal antibodies (Kleina
nd Grubman, 1992). This ensures that equal amounts of
otal radiolabeled protein from cells infected with differ-
nt viruses were compared, and the relative amounts of
MDV antigens produced in those infections were deter-
ined by immunoprecipitation. The samples were re-
olved by SDS–polyacrylamide gel electrophoresis on a
5% gel (Laemmli, 1970).
Mouse and swine sera were also tested for the pres-
nce of FMDV-specific antibodies by performing RIPs.
35S]Methionine-labeled FMDV A12-infected LK cell ly-
ates (250,000 cpm per sample) were immunoprecipi-
ated with pooled or individual mouse sera, or individual
wine sera were obtained at various times postinocula-
ion.
noculation of BALB/c mice with Ad5-FMDV
ybrid virus
Nine-week-old BALB/c mice (certified murine adeno-
7irus-free) were inoculated with 5 3 10 pfu/mouse Ad5-
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504 MAYR, CHINSANGARAM, AND GRUBMAN12X3CWT or Ad5-P12X3CMUT in 50 ml of 13 PBS, or
ith PBS alone, by the im route. Each experimental
roup contained five mice, except the PBS control group,
hich contained four. At 3 and 5 weeks postinoculation,
he mice were bled from the tail and serum was col-
ected. At 6 weeks postinoculation, the mice were
oosted with an additional 5 3 107 pfu of the same virus
ith which they were initially inoculated. The mice were
hen bled at 2, 5, and 15 weeks postboost (8, 11, and 21
eeks post-initial inoculation). A PRN assay of pooled
era from fresh 6- to 8-week old BALB/c mice showed
hat the mice had no neutralizing antibodies against
MDV prior to inoculation (data not shown).
noculation of swine with Ad5-P12X3CWT virus
Six 6- to 8-week-old Yorkshire/Bluepoint swine,
oused in the same room, were divided into a vaccine
est group and a control group, each containing three
nimals. The housing of the animals all in one room
llows us to determine before challenge if the vaccine is
assed from animal to animal by measuring seroconver-
ion against FMDV. We did not expect animal-to-animal
ransfer of the vaccine, but it was necessary to demon-
trate this experimentally. The common area also en-
ures that after challenge, the vaccinated animals will be
xposed to high and sustained levels of FMDV virus
hallenge as all three of the control swine develop signs
f FMDV infection. The vaccine test group was inocu-
ated im with 1 3 108 pfu/swine of Ad5-P12X3CWT in 1 ml
f PBS and the control group with PBS. The swine were
oosted at 4 weeks with an equivalent amount of Ad5-
12X3CWT virus or PBS. At 8 weeks post-initial inocula-
ion, a single animal from the control group was inocu-
ated intradermally in the snout and by a combination of
ntradermal (coronary band and heel bulb) and skin scar-
fication (coronary band) on one foot with a total of 5 3
04 infectious units of virulent cattle-passaged FMDV
ype A12. Rectal temperature data and clinical signs,
ncluding lameness and vesicular lesions, were re-
orded daily. Temperature of over 40°C for 2 or more
onsecutive days was considered to constitute a fever.
t the time of necropsy, 2 weeks postchallenge, the
umber of digits affected by the disease was recorded
s a lesion score for each animal (see Table 1). Serum
amples were collected prior to inoculation and at
eekly intervals throughout the course of the experi-
ent.
laque reduction neutralization assay
At 3, 5, 8, 11, and 21 weeks postinoculation, pooled
ouse sera were tested in a PRN assay (Mason et al.,
997). Briefly, diluted serum was mixed with an equal
olume of a dilution of FMDV which would result in
0–100 plaques. This mixture was applied to duplicateells of a six-well plate of BHK-21 cells. After adsorption
f the virus for 1 h at 37°C, the inoculum was aspirated
nd the cells were overlaid with 2 ml of 0.6% gum traga-
anth and incubated 24 h at 37°C before staining with
rystal violet to visualize the plaques. Individual sera
rom Ad5-P12X3CWT-inoculated mice at 5 and 8 weeks
ost-initial inoculation were also tested. Individual swine
era obtained throughout the experiment were also
ested in a PRN assay.
Neutralizing titers were reported as the serum dilution
ielding a 70% reduction in the number of plaques
PRN70).
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